T2ND34 Stock Overview
A medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Tandem Diabetes Care, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.91 |
| 52 Week High | US$18.90 |
| 52 Week Low | US$6.13 |
| Beta | 1.27 |
| 11 Month Change | -17.03% |
| 3 Month Change | 25.29% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| T2ND34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -3.8% | -0.8% | 1.9% |
| 1Y | n/a | -2.6% | -1.4% |
Return vs Industry: Insufficient data to determine how T2ND34 performed against the BR Medical Equipment industry.
Return vs Market: Insufficient data to determine how T2ND34 performed against the BR Market.
Price Volatility
| T2ND34 volatility | |
|---|---|
| T2ND34 Average Weekly Movement | 10.4% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 9.1% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: T2ND34's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine T2ND34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 2,400 | John Sheridan | www.tandemdiabetes.com |
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body.
Tandem Diabetes Care, Inc. Fundamentals Summary
| T2ND34 fundamental statistics | |
|---|---|
| Market cap | R$14.55b |
| Earnings (TTM) | -R$790.78m |
| Revenue (TTM) | R$4.30b |
3.4x
P/S Ratio-18.4x
P/E RatioIs T2ND34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| T2ND34 income statement (TTM) | |
|---|---|
| Revenue | US$770.01m |
| Cost of Revenue | US$390.55m |
| Gross Profit | US$379.46m |
| Other Expenses | US$520.91m |
| Earnings | -US$141.45m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.19 |
| Gross Margin | 49.28% |
| Net Profit Margin | -18.37% |
| Debt/Equity Ratio | 143.0% |
How did T2ND34 perform over the long term?
See historical performance and comparison